2020
DOI: 10.3390/ijms21072409
|View full text |Cite
|
Sign up to set email alerts
|

Sorafenib Treatment and Modulation of the Sphingolipid Pathway Affect Proliferation and Viability of Hepatocellular Carcinoma In Vitro

Abstract: Hepatocellular carcinoma (HCC) shows a remarkable heterogeneity and is recognized as a chemoresistant tumor with dismal prognosis. In previous studies, we observed significant alterations in the serum sphingolipids of patients with HCC. This study aimed to investigate the in vitro effects of sorafenib, which is the most widely used systemic HCC medication, on the sphingolipid pathway as well as the effects of inhibiting the sphingolipid pathway in HCC. Huh7.5 and HepG2 cells were stimulated with sorafenib, and… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
8
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 12 publications
(8 citation statements)
references
References 60 publications
(73 reference statements)
0
8
0
Order By: Relevance
“…Therefore, after a day, cells were treated with either sorafenib at a final concentration of 5 mmol/L or vehicle (DMSO), which is further consistent with the current literature. 49,50 Fresh growth media with or without sorafenib was provided for 24-48-72 h and 1 week. MTS reagent (20 mL/well) was added to the cells followed by incubation for 4 hours in a 5% CO 2 humidified incubator at 37 C, and the absorbance was measured at 490 nm, at 0, 24, 48, and 74 hours, and after 1 week Q121 .…”
Section: Cell Proliferation Assaymentioning
confidence: 99%
“…Therefore, after a day, cells were treated with either sorafenib at a final concentration of 5 mmol/L or vehicle (DMSO), which is further consistent with the current literature. 49,50 Fresh growth media with or without sorafenib was provided for 24-48-72 h and 1 week. MTS reagent (20 mL/well) was added to the cells followed by incubation for 4 hours in a 5% CO 2 humidified incubator at 37 C, and the absorbance was measured at 490 nm, at 0, 24, 48, and 74 hours, and after 1 week Q121 .…”
Section: Cell Proliferation Assaymentioning
confidence: 99%
“…Therefore, after a day, cells were treated with either sorafenib at a final concentration of 5 mmol/L or vehicle (DMSO), which is further consistent with the current literature. 49,50 Fresh growth media with or without sorafenib was provided for 24-48-72 h and 1 week. MTS reagent (20 mL/well) was added to the cells followed by incubation for 4 hours in a 5% CO 2 humidified incubator at 37 C, and the absorbance was measured at 490 nm, at 0, 24, 48, and 74 hours, and after 1 week.…”
Section: Cell Proliferation Assaymentioning
confidence: 99%
“…In colorectal cancer, the low expression of SPTLC1 leads to worse prognosis (40), in renal cell carcinoma, it inhibits cell proliferation (41) and in lymphoma patients, a mutation of SPTLC1 increasing its enzymatic activity, sensitized BCR-ABL tumors to imatinib (42). On the other hand, serum ceramides and sphingolipids such as S1P and SA1P are increased in patients with HCC but not in cirrhotic controls (43), and the blockade of sphingolipids in Huh7 and HepG2 cell lines led to increased susceptibility to sorafenib (44). More broadly, it has been described that sphingolipids are produced in higher amounts in cancer cells and that sphingosine-1-phosphate (S1P) intermediate promotes proliferation, migration and EMT (45) and regulates the interphase with other cells through the inhibition of sindecan 1 (46).…”
Section: Discussionmentioning
confidence: 99%